A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
A legfontosabb adatok
- Ki végzi
- Kedrion S.p.A.
- Hol
- Bucharest, Cluj-Napoca és Craiova (Románia)Mind a 3 helyszín megnézéseMég 7 másik országban, 23 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2025. aug. 13.
- Várható befejezés
- 2027. jan.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Kedrion IVIG 10%
- A regiszteradat frissítve
- 2026. október 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with chronic primary immune thrombocytopenia (ITP), a condition with a low platelet count. Everyone gets one course of Kedrion IVIg 10% given into a vein.
- Életkor
- 18 to 70 years
- Nem
- All sexes
- A betegség stádiuma
- Chronic primary ITP lasting more than 12 months, as defined by the International Working Group.
- Korábbi kezelés
- People who did not respond to IVIg or anti-D Ig before cannot join. No IVIg, anti-D immunoglobulin or platelet-raising drugs within 3 weeks, with some exceptions for stable doses. No rituximab within 6 months.
- Biomarker vagy leletérték
- Platelet count below 30 × 10^9/L on two counts at least one day apart, and again before the first infusion.
A részvétel fő kizáró okai
- ITP caused by another disease or a drug, or Evans syndrome
- Hepatitis B, hepatitis C or HIV infection
- Past blood clots, stroke, heart attack, or high risk of clots
- Severe heart, liver or kidney disease, or uncontrolled high blood pressure
- Cancer within the last 3 years, with some skin and cervix exceptions
A regiszter feltételei, szó szerint
Mind a 37 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female, 18-70 years of age
- Patient has signed the ICF
- Diagnosis of chronic (> 12 months duration) ITP as defined by the International Working Group
- Mean screening platelet count of < 30 × 10\^9/L from two qualifying counts measured at least one calendar day apart. The first qualifying count can be from historical data if measured within 7 days prior to screening. The second qualifying count will be measured within 7 days before the first KIg10 infusion
- A pre-infusion platelet count of < 30 × 10\^9/L at the Baseline Visit
- Patient is willing to comply with all requirements of the protocol
- Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and agree to employ adequate birth control measures during the study
- Authorization to access personal health information
Ki nem vehet részt
- Patient unresponsive previously to IVIg or anti-D Ig treatment
- Patient with known Immunoglobulin A (IgA) deficiency and antibodies against IgA
- Received any blood, blood product, or blood derivative within 1 month of the Baseline Visit
- Received rituximab within 6 months of the Baseline Visit
- Received recombinant activated factor VII within 7 days of the Baseline Visit
- Had therapy with live attenuated virus vaccines within 3 months of the Baseline Visit
- Patients with secondary ITP (all forms of immune-mediated thrombocytopenia except primary ITP). e.g., lupus erythematosus, rheumatoid arthritis, drug-related ITP, and Human Immunodeficiency Virus (HIV)
- Patients with Evans Syndrome
- Patients known to be infected with hepatitis B virus, hepatitis C virus, or HIV
- History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction
- Patient with a history of hypersensitivity to IVIg, other injectable forms of IVIg, or to any of the excipients
- Participants with known inherited thrombocytopenia. e.g., MYH-9 disorders
- Participants with myelodysplastic syndrome (MDS)
- Uncontrolled hypertension [i.e., diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used
- Congestive heart failure as per New York Heart Association III/IV, cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity
- Patients with significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia
- History of a malignant disease within 3 years of the Baseline Visit other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin
- Any condition that the Investigator believes is likely to interfere with evaluation of the IMP or with satisfactory conduct of the trial
- Administration of IVIg, anti-D immunoglobulin, Mercaptopurine, Vinca alkaloid, or platelet enhancing drugs (including thrombopoietin receptor agonists [TPO-RA], immunosuppressive, or other immunomodulatory drugs) within 3 weeks of the Baseline Visit, except for:; patients on a stable dose of TPO-RA within 4 weeks of the Baseline Visit; patients on a stable dose of Mycophenolate Mofetil within 3 months of the Baseline Visit; patients on stable dose of Danazol within 3 months of the Baseline Visit; long-term corticosteroid therapy for ITP, when the dose had been stable within 3 weeks of the Baseline Visit and no dosage change was planned until the EOS Visit; long-term azathioprine, cyclophosphamide, or attenuated androgen therapy when the dose had been stable within 3 months of the Baseline Visit, and no dosage change was planned until after study completion. Treatment with any other products licensed for primary chronic ITP is also exclusive. An appropriate wash-out period must be determined in case of patients who might be eligible for treatment with IVIg
- Had a platelet transfusion or receipt of blood products containing platelets within 7 days of Visit 1 (Day 1)
- Patients with hyperproteinemia, increased serum viscosity, and/or hyponatremia
- Severe liver or kidney disease (normal reference ranges of laboratory doing the analysis):; alanine aminotransferase (ALT) or aspartate amino transferase (AST) 2.5x > upper limit of normal (ULN); creatinine > 120 μmol/L; blood urea nitrogen (BUN) > 2.5x ULN
- Signs of severe anemia: Hemoglobin of less than 7 g/dL, hemodynamically unstable due to active bleeding, and/or when evidence of end-organ ischemia secondary to severe anemia is present
- Patients incapable of giving informed consent
- Splenectomy within 4 weeks of the Baseline Visit or planned splenectomy throughout the study period
- Use of loop diuretics within 1 week of the Baseline Visit
- Patients at high risk of thrombotic events
- Body mass index > 40 kg/m2 or an IVIg dose that puts the patient at risk of fluid overload
- Patient has participated in an interventional, investigational clinical study within 30 days of the Baseline Visit or within 5 half-lives of the investigational medicinal product (IMP) under investigation
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Helyszínek itt: Románia
Még 7 másik országban, 23 helyszínen
- Spitalul Clinic ColțeaBucharest, RomániaRésztvevőt keres
- Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-NapocaCluj-Napoca, RomániaRésztvevőt keres
- Spitalul Clinic Municipal Filantropia CraiovaCraiova, RomániaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
A vizsgálat csoportja
- 2 g/kg Kedrion IVIg 10%A vizsgált kezelés
Subjects will receive one course of treatment with 2 g/kg of Kedrion IVIg 10% administered over 2 days
Kezelés: Kedrion IVIG 10%
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07059000: ki vehet részt
- A regiszteradat frissítve
- 2026. október 22.